Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 514 participants.
Also called NCT05691244
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 514 participants
- Sponsor
- Registry
-
NCT05691244
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Germany, Spain, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT05691244. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-24 (actual); primary completion 2027-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
- Acronym
- RESPECT-ETB
- Condition
- Acute Ischemic Stroke
- Condition
- Cerebral Stroke
- Intervention (Drug)
- Drug: Normal Saline
- Intervention (Drug)
- Sovateltide
- Lead sponsor
- Pharmazz, Inc.
Record details
- Record id
cardio:ct-nct05691244- Content hash
88bee31a935a8b448e9ae1a8c9aaf36107bc36e2b2a0e131ee8954534f517407